{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Retrieve grapg info and evaluate results across different models"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "# from transformers import pipeline\n",
    "\n",
    "# ner_pipeline = pipeline(\"ner\", model=\"d4data/biomedical-ner-all\")\n",
    "# text = \"Patient John Doe was diagnosed with diabetes at Mayo Clinic.\"\n",
    "# entities = ner_pipeline(text)\n",
    "\n",
    "# print entities only"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/Users/zhangbobby/Desktop/Capstone/GrapgRAG_experiments/.venv/lib/python3.11/site-packages/tqdm/auto.py:21: TqdmWarning: IProgress not found. Please update jupyter and ipywidgets. See https://ipywidgets.readthedocs.io/en/stable/user_install.html\n",
      "  from .autonotebook import tqdm as notebook_tqdm\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from dotenv import load_dotenv\n",
    "import os\n",
    "from langchain_neo4j import Neo4jGraph\n",
    "from libs import create_vector_index, generate_response, run_trial, create_md , get_entities\n",
    "\n",
    "# from lib import create_vector_index, generate_response, run_trial,create_md\n",
    "from dotenv import load_dotenv\n",
    "import pandas as pd\n",
    "\n",
    "# from sentence_transformers import SentenceTransformer\n",
    "\n",
    "# Force reload of the .env file\n",
    "load_dotenv(override=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "graph = Neo4jGraph(\n",
    "    url=os.getenv(\"NEO4J_URL\"),\n",
    "    username=os.getenv(\"NEO4J_USERNAME\"),\n",
    "    password=os.getenv(\"NEO4J_PASSWORD\"),\n",
    ")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## create vector index"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "create_vector_index(graph, \"entities\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Question = \"Among critically ill patients in septic shock, does low-dose hydrocortisone therapy improve survival?\"\n",
    "Question = \"Does mechanical ventilation with a lower tidal volume result in decreased mortality with acute lung injury and acute respiratory distress syndrome?\"\n",
    "response, _ = generate_response(graph, Question)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "=== Detailed Response Info ===\n",
      "Model used: gpt-4-turbo-2024-04-09\n",
      "Response content: [\"ACURASYS.pdf\"]\n",
      "Finish reason: stop\n",
      "Prompt tokens: 10945\n",
      "Completion tokens: 8\n",
      "Total tokens: 10953\n"
     ]
    }
   ],
   "source": [
    "# Method 2: Print detailed response information\n",
    "print(\"\\n=== Detailed Response Info ===\")\n",
    "print(f\"Model used: {response.model}\")\n",
    "print(f\"Response content: {response.choices[0].message.content}\")\n",
    "print(f\"Finish reason: {response.choices[0].finish_reason}\")\n",
    "print(f\"Prompt tokens: {response.usage.prompt_tokens}\")\n",
    "print(f\"Completion tokens: {response.usage.completion_tokens}\")\n",
    "print(f\"Total tokens: {response.usage.total_tokens}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Context:  Mechanical ventilation UNDERWENT_BY patients,\n",
      " patients SCREENED_FOR eligibility criteria,\n",
      " patients MET_CRITERIA_FOR severe sepsis,\n",
      " patients MET_CRITERIA_FOR severe sepsis, severe sepsis HAS_PHYSIOLOGICAL_ADVANTAGE albumin administration,\n",
      " patients MET_CRITERIA_FOR severe sepsis, severe sepsis DIAGNOSED_WITH 1818 patients,\n",
      " patients MET_CRITERIA_FOR severe sepsis, severe sepsis MET_CRITERIA_FOR patient,\n",
      " patients MET_CRITERIA_FOR severe sepsis, severe sepsis HAS_ADVANTAGE albumin,\n",
      " patients MET_CRITERIA_FOR severe sepsis, severe sepsis STUDIED_IN tissue factor pathway inhibitor,\n",
      " patients MET_CRITERIA_FOR severe sepsis, severe sepsis USED_FOR human albumin,\n",
      " patients MET_CRITERIA_FOR severe sepsis, severe sepsis FOCUSED_ON Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial,\n",
      " patients MET_CRITERIA_FOR severe sepsis, severe sepsis ASSOCIATED_WITH septic shock,\n",
      " patients MET_CRITERIA_FOR severe sepsis, severe sepsis ASSOCIATED_WITH early phase,\n",
      " patients RECEIVED_CARE_FROM clinicians,\n",
      " patients CONDITION septic shock,\n",
      " patients CONDITION septic shock, septic shock RELATED_TO Practice guidelines,\n",
      " patients CONDITION septic shock, septic shock RELATED_TO prognostic classification,\n",
      " patients CONDITION septic shock, septic shock HAS_IMPORTANCE adrenal insufficiency,\n",
      " patients CONDITION septic shock, septic shock HAS_CONDITION patients,\n",
      " patients CONDITION septic shock, septic shock STUDIED_IN ADRENAL study,\n",
      " patients CONDITION septic shock, septic shock USED_FOR Glucocorticoids,\n",
      " patients CONDITION septic shock, septic shock USED_FOR Fludrocortisone,\n",
      " patients CONDITION septic shock, septic shock USED_FOR corticosteroids,\n",
      " patients CONDITION septic shock, septic shock USED_FOR hydrocortisone,\n",
      " patients CONDITION septic shock, septic shock USED_FOR Hydrocortisone,\n",
      " patients CONDITION septic shock, septic shock DEFINED_AS presence of a clinically or microbiologically documented condition,\n",
      " patients CONDITION septic shock, septic shock ASSOCIATED_WITH cortisol response to corticotrophin,\n",
      " patients CONDITION septic shock, septic shock ASSOCIATED_WITH cortisol levels,\n",
      " patients CONDITION septic shock, septic shock ASSOCIATED_WITH hydrocortisone,\n",
      " patients CONDITION septic shock, septic shock ASSOCIATED_WITH acute respiratory distress syndrome,\n",
      " patients CONDITION septic shock, septic shock ASSOCIATED_WITH severe sepsis,\n",
      " patients CONDITION septic shock, septic shock ASSOCIATED_WITH neuromuscular weakness,\n",
      " patients SAFETY_OUTCOME neurologic sequelae,\n",
      " patients SAFETY_OUTCOME neurologic sequelae, neurologic sequelae HAS_RISK hydrocortisone plus fludrocortisone,\n",
      " patients SAFETY_OUTCOME neurologic sequelae, neurologic sequelae INCLUDES cognitive impairment,\n",
      " patients SAFETY_OUTCOME neurologic sequelae, neurologic sequelae INCLUDES muscle weakness,\n",
      " patients SAFETY_OUTCOME gastrointestinal bleeding,\n",
      " patients SAFETY_OUTCOME hyperglycemia,\n",
      " patients SAFETY_OUTCOME hyperglycemia, hyperglycemia HAS_MORE_COMMON hydrocortisone-plus-fludrocortisone group,\n",
      " patients SAFETY_OUTCOME hyperglycemia, hyperglycemia HAS_RISK Hydrocortisone plus Fludrocortisone,\n",
      " patients SAFETY_OUTCOME hyperglycemia, hyperglycemia HAS_RISK hydrocortisone plus fludrocortisone,\n",
      " patients SAFETY_OUTCOME hyperglycemia, hyperglycemia ASSOCIATED_WITH hydrocortisone,\n",
      " patients SAFETY_OUTCOME superinfection,\n",
      " patients SAFETY_OUTCOME superinfection, superinfection HAS_ADVERSE_EFFECT glucocorticoids,\n",
      " patients SAFETY_OUTCOME superinfection, superinfection HAS_RISK Hydrocortisone plus Fludrocortisone,\n",
      " patients SAFETY_OUTCOME superinfection, superinfection ASSOCIATED_WITH hydrocortisone,\n",
      " patients DISCHARGED_BY_DAY day 90,\n",
      " patients DISCHARGED_BY_DAY day 28,\n",
      " patients DISCHARGED_BY_DAY day 28, day 28 HAS_HIGHER_VASOPRESSOR_FREE_DAYS hydrocortisone-plus-fludrocortisone group,\n",
      " patients DISCHARGED_BY_DAY day 28, day 28 APPLIED_UNTIL lower tidal volumes,\n",
      " patients DISCHARGED_BY_DAY day 28, day 28 ASSESSED_UP_TO ICU-acquired weakness,\n",
      " patients DISCHARGED_BY_DAY day 28, day 28 ASSESSED_AT days free of mechanical ventilation,\n",
      " patients DISCHARGED_BY_DAY day 28, day 28 ASSESSED_AT days free of organ dysfunction,\n",
      " patients DISCHARGED_BY_DAY day 28, day 28 ASSESSED_AT days not in the ICU,\n",
      " patients DISCHARGED_BY_DAY day 28, day 28 ASSESSED_AT days not in the hospital,\n",
      " patients DISCHARGED_BY_DAY day 28, day 28 ASSESSED_AT in-hospital death,\n",
      " patients DISCHARGED_BY_DAY day 28, day 28 ASSESSED_AT control group,\n",
      " patients DISCHARGED_BY_DAY day 28, day 28 ASSESSED_AT intervention group,\n",
      " patients DISCHARGED_FROM hospital,\n",
      " patients DISCHARGED_FROM hospital, hospital MEASURED_IN rate of death,\n",
      " patients DISCHARGED_FROM ICU,\n",
      " patients DISCHARGED_FROM ICU, ICU PARTICIPATED_IN trial,\n",
      " patients DISCHARGED_FROM ICU, ICU DENOTES intensive care unit,\n",
      " patients DISCHARGED_FROM ICU, ICU STANDS_FOR intensive care unit,\n",
      " patients DISCHARGED_FROM ICU, ICU MEASURED_IN rate of death,\n",
      " severe septic shock OBSERVED_IN patients,\n",
      " patients HAS_RESPONSE_TO corticotropin,\n",
      " patients HAS_RESPONSE_TO corticotropin, corticotropin NO_RESPONSE_IN subgroup of patients,\n",
      " patients HAS_RESPONSE_TO corticotropin, corticotropin NO_EFFECT subgroup of patients who had no response,\n",
      " patients HAS_RESPONSE_TO corticotropin, corticotropin HAD_RESPONSE_TO patients,\n",
      " patients HAS_RESPONSE_TO corticotropin, corticotropin UNKNOWN_RESPONSE 4 patients in placebo group,\n",
      " patients HAS_RESPONSE_TO corticotropin, corticotropin UNKNOWN_RESPONSE 8 patients in hydrocortisone group,\n",
      " patients HAS_RESPONSE_TO corticotropin, corticotropin RESPONSE 136 patients in placebo group,\n",
      " patients HAS_RESPONSE_TO corticotropin, corticotropin RESPONSE 118 patients in hydrocortisone group,\n",
      " patients HAS_RESPONSE_TO corticotropin, corticotropin RESPONSE 254 patients,\n",
      " patients HAS_RESPONSE_TO corticotropin, corticotropin NO_RESPONSE 499 patients,\n",
      " patients HAS_RESPONSE_TO corticotropin, corticotropin NO_RESPONSE 233 patients,\n",
      " patients HAS_RESPONSE_TO corticotropin, corticotropin NO_RESPONSE 125 patients in hydrocortisone group,\n",
      " patients HAS_RESPONSE_TO corticotropin, corticotropin NO_RESPONSE 108 patients in placebo group,\n",
      " patients HAD_RESPONSE_TO corticotropin,\n",
      " patients HAD_RESPONSE_TO corticotropin, corticotropin NO_RESPONSE_IN subgroup of patients,\n",
      " patients HAD_RESPONSE_TO corticotropin, corticotropin NO_EFFECT subgroup of patients who had no response,\n",
      " patients HAD_RESPONSE_TO corticotropin, corticotropin HAS_RESPONSE_TO patients,\n",
      " patients HAD_RESPONSE_TO corticotropin, corticotropin UNKNOWN_RESPONSE 4 patients in placebo group,\n",
      " patients HAD_RESPONSE_TO corticotropin, corticotropin UNKNOWN_RESPONSE 8 patients in hydrocortisone group,\n",
      " patients HAD_RESPONSE_TO corticotropin, corticotropin RESPONSE 136 patients in placebo group,\n",
      " patients HAD_RESPONSE_TO corticotropin, corticotropin RESPONSE 118 patients in hydrocortisone group,\n",
      " patients HAD_RESPONSE_TO corticotropin, corticotropin RESPONSE 254 patients,\n",
      " patients HAD_RESPONSE_TO corticotropin, corticotropin NO_RESPONSE 499 patients,\n",
      " patients HAD_RESPONSE_TO corticotropin, corticotropin NO_RESPONSE 233 patients,\n",
      " patients HAD_RESPONSE_TO corticotropin, corticotropin NO_RESPONSE 125 patients in hydrocortisone group,\n",
      " patients HAD_RESPONSE_TO corticotropin, corticotropin NO_RESPONSE 108 patients in placebo group,\n",
      " activated protein C USED_BY patients,\n",
      " antithrombin USED_BY patients,\n",
      " patients REMAINS hypotensive after at least 1 hour of resuscitation with fluids and vasopressors,\n",
      " Inotropic or vasopressor support RECEIVED_BY patients,\n",
      " renal-replacement therapy RECEIVED_BY patients,\n",
      " renal-replacement therapy RECEIVED_BY patients, renal-replacement therapy USED_BEFORE randomization,\n",
      " renal-replacement therapy RECEIVED_BY patients, renal-replacement therapy ASSESSED_IN post hoc analyses,\n",
      " patients MONITORED_FOR cardiovascular, renal, and hepatic failure; coagulation abnormalities; and the need for assisted ventilation,\n",
      " patients HAS_CONDITION septic shock,\n",
      " patients HAS_CONDITION septic shock, septic shock CONDITION patients,\n",
      " patients HAS_CONDITION septic shock, septic shock RELATED_TO Practice guidelines,\n",
      " patients HAS_CONDITION septic shock, septic shock RELATED_TO prognostic classification,\n",
      " patients HAS_CONDITION septic shock, septic shock HAS_IMPORTANCE adrenal insufficiency,\n",
      " patients HAS_CONDITION septic shock, septic shock STUDIED_IN ADRENAL study,\n",
      " patients HAS_CONDITION septic shock, septic shock USED_FOR Glucocorticoids,\n",
      " patients HAS_CONDITION septic shock, septic shock USED_FOR Fludrocortisone,\n",
      " patients HAS_CONDITION septic shock, septic shock USED_FOR corticosteroids,\n",
      " patients HAS_CONDITION septic shock, septic shock USED_FOR hydrocortisone,\n",
      " patients HAS_CONDITION septic shock, septic shock USED_FOR Hydrocortisone,\n",
      " patients HAS_CONDITION septic shock, septic shock DEFINED_AS presence of a clinically or microbiologically documented condition,\n",
      " patients HAS_CONDITION septic shock, septic shock ASSOCIATED_WITH cortisol response to corticotrophin,\n",
      " patients HAS_CONDITION septic shock, septic shock ASSOCIATED_WITH cortisol levels,\n",
      " patients HAS_CONDITION septic shock, septic shock ASSOCIATED_WITH hydrocortisone,\n",
      " patients HAS_CONDITION septic shock, septic shock ASSOCIATED_WITH acute respiratory distress syndrome,\n",
      " patients HAS_CONDITION septic shock, septic shock ASSOCIATED_WITH severe sepsis,\n",
      " patients HAS_CONDITION septic shock, septic shock ASSOCIATED_WITH neuromuscular weakness,\n",
      " patients ASSIGNED_TO_RECEIVE mechanical ventilation,\n",
      " patients ASSIGNED_TO_RECEIVE mechanical ventilation, mechanical ventilation EARLIER_CESSATION hydrocortisone,\n",
      " patients ASSIGNED_TO_RECEIVE mechanical ventilation, mechanical ventilation COLLECTED_ON data,\n",
      " patients ASSIGNED_TO_RECEIVE mechanical ventilation, mechanical ventilation HAS_SHORTER_TIME_TO_WEANING hydrocortisone-plus-fludrocortisone group,\n",
      " patients ASSIGNED_TO_RECEIVE mechanical ventilation, mechanical ventilation SHORTENED_BY conservative fluid strategy,\n",
      " patients ASSIGNED_TO_RECEIVE mechanical ventilation, mechanical ventilation ASSESSED_IN post hoc analyses,\n",
      " patients ASSIGNED_TO_RECEIVE mechanical ventilation, mechanical ventilation USED_FOR acute lung injury,\n",
      " patients ASSIGNED_TO_RECEIVE mechanical ventilation, mechanical ventilation USED_FOR acute respiratory distress syndrome,\n",
      " patients ASSIGNED_TO_RECEIVE mechanical ventilation, mechanical ventilation CONTRIBUTES_TO Multiple system organ failure,\n",
      " patients ASSIGNED_TO_RECEIVE mechanical ventilation, mechanical ventilation CAUSES lung injury,\n",
      " patients ASSIGNED_TO_RECEIVE mechanical ventilation, mechanical ventilation HAS_TREATMENT acute respiratory distress syndrome,\n",
      " patients ASSIGNED_TO_RECEIVE mechanical ventilation, mechanical ventilation USED_IN lower tidal volume,\n",
      " patients ASSIGNED_TO_RECEIVE mechanical ventilation, mechanical ventilation PERFORMED_WITH endotracheal tube,\n",
      " patients ASSIGNED_TO_RECEIVE mechanical ventilation, mechanical ventilation UNDERGOING Patients with septic shock,\n",
      " patients ASSIGNED_TO_RECEIVE mechanical ventilation, mechanical ventilation UNDERGOING patients with septic shock,\n",
      " patients ASSIGNED_TO_RECEIVE mechanical ventilation, mechanical ventilation UNDERGOING patients,\n",
      " patients ASSIGNED_TO_RECEIVE mechanical ventilation, mechanical ventilation HAS_CHARACTERISTIC lower tidal volume,\n",
      " patients ASSIGNED_TO_RECEIVE mechanical ventilation, mechanical ventilation HAS_CHARACTERISTIC lighter sedation targets,\n",
      " patients ASSIGNED_TO_RECEIVE mechanical ventilation, mechanical ventilation INVOLVES traditional tidal volumes,\n",
      " patients ASSIGNED_TO_RECEIVE mechanical ventilation, mechanical ventilation INVOLVES lower tidal volumes,\n",
      " patients ASSIGNED_TO_RECEIVE mechanical ventilation, mechanical ventilation CONDUCTED_IN intensive care unit (ICU),\n",
      " patients ASSIGNED_TO_RECEIVE mechanical ventilation, mechanical ventilation AFFECTS survival and outcomes after discharge from the intensive care unit,\n",
      " patients HAD_CONDITIONS_WITH 6-month mortality rate of more than 50 percent,\n",
      " patients HAD_BURNS_OVER 30 percent of their body-surface area,\n",
      " patients WEIGHED_MORE_THAN 1 kg per centimeter of height,\n",
      " patients GAVE_CONSENT trial,\n",
      " patients GAVE_CONSENT trial, trial DID_NOT_ASSESS long-term neuromuscular weakness,\n",
      " patients GAVE_CONSENT trial, trial RECORDED_IN bacteremia,\n",
      " patients GAVE_CONSENT trial, trial RECORDED_IN fungemia,\n",
      " patients GAVE_CONSENT trial, trial HAS_NO SUSARs,\n",
      " patients GAVE_CONSENT trial, trial HAS_LIMITATION use of albumin solutions with greater concentration,\n",
      " patients GAVE_CONSENT trial, trial HAS_LIMITATION only one third of patients enrolled during early phase of severe sepsis,\n",
      " patients GAVE_CONSENT trial, trial HAS_LIMITATION observed mortality at 28 days lower than expected,\n",
      " patients GAVE_CONSENT trial, trial REMAINED_IN 3686 patients,\n",
      " patients GAVE_CONSENT trial, trial WITHDREW_OR_NO_CONSENT 114 patients,\n",
      " patients GAVE_CONSENT trial, trial LOCATION_OF 69 medical–surgical ICUs,\n",
      " patients GAVE_CONSENT trial, trial IDENTIFIED_IN 5501 eligible patients,\n",
      " patients GAVE_CONSENT trial, trial SPONSORED George Institute for Global Health, Australia,\n",
      " patients GAVE_CONSENT trial, trial OVERSAW data and safety monitoring board,\n",
      " patients GAVE_CONSENT trial, trial SUSPENDED_FROM_TO October 25, 2011 to May 12, 2012,\n",
      " patients GAVE_CONSENT trial, trial SUSPENDED_FROM_TO July 22, 2014 to October 7, 2014,\n",
      " patients GAVE_CONSENT trial, trial COMPLETED_ON December 23, 2015,\n",
      " patients GAVE_CONSENT trial, trial SUSPENDED_DATE October,\n",
      " patients GAVE_CONSENT trial, trial SUSPENDED twice,\n",
      " patients GAVE_CONSENT trial, trial EXPIRATION_REACHED trial agents,\n",
      " patients GAVE_CONSENT trial, trial ENROLLED_PATIENTS 1241,\n",
      " patients GAVE_CONSENT trial, trial TERMINATED_BY sponsor,\n",
      " patients GAVE_CONSENT trial, trial EFFECT_ASSESSED_IN drotrecogin alfa (activated),\n",
      " patients GAVE_CONSENT trial, trial ELIGIBLE_FOR Trial Patients,\n",
      " patients GAVE_CONSENT trial, trial DESIGNED_AS 2-by-2 factorial design,\n",
      " patients GAVE_CONSENT trial, trial INCLUDED 1241 patients,\n",
      " patients GAVE_CONSENT trial, trial PROVIDES_EVIDENCE role of hydrocortisone,\n",
      " patients GAVE_CONSENT trial, trial MONITORED_BY independent data and safety monitoring board,\n",
      " patients GAVE_CONSENT trial, trial DESIGNED trial management committee,\n",
      " patients GAVE_CONSENT trial, trial PARTICIPATED_IN 34 participating centers,\n",
      " patients GAVE_CONSENT trial, trial PARTICIPATED_IN G.R. Bernard,\n",
      " patients GAVE_CONSENT trial, trial PARTICIPATED_IN B. deBoisblanc,\n",
      " patients GAVE_CONSENT trial, trial PARTICIPATED_IN R.D. Hite,\n",
      " patients GAVE_CONSENT trial, trial PARTICIPATED_IN A.F. Connors,\n",
      " patients GAVE_CONSENT trial, trial PARTICIPATED_IN A.P. Wheeler,\n",
      " patients GAVE_CONSENT trial, trial PARTICIPATED_IN B.T. Thompson,\n",
      " patients GAVE_CONSENT trial, trial PARTICIPATED_IN A.L. Harabin,\n",
      " patients GAVE_CONSENT trial, trial PARTICIPATED_IN D. Hayden,\n",
      " patients GAVE_CONSENT trial, trial PARTICIPATED_IN H.P. Wiedemann,\n",
      " patients GAVE_CONSENT trial, trial PARTICIPATED_IN ICU,\n",
      " patients GAVE_CONSENT trial, trial FOUND_EFFICACIOUS lower tidal volumes,\n",
      " patients GAVE_CONSENT trial, trial SCREENED_BETWEEN June 8, 2000, and October 3, 2005,\n",
      " patients GAVE_CONSENT trial, trial SCREENED_PATIENTS 10,511 patients,\n",
      " patients GAVE_CONSENT trial, trial RESUMED_ON July 23, 2003,\n",
      " patients GAVE_CONSENT trial, trial HALTED_ON July 25, 2002,\n",
      " patients GAVE_CONSENT trial, trial CONDUCTED_AT North American centers,\n",
      " patients GAVE_CONSENT trial, trial REVIEWED Office of Human Research Protection,\n",
      " patients GAVE_CONSENT trial, trial EXCLUDES patients who had previously received neuromuscular blockade,\n",
      " patients GAVE_CONSENT trial, trial ANALYZES duration of ARDS,\n",
      " patients GAVE_CONSENT trial, trial ANALYZES severity of ARDS,\n",
      " patients GAVE_CONSENT trial, trial USES_TEST Wald test,\n",
      " patients GAVE_CONSENT trial, trial HAS_STOPPING_RULE superiority of either group,\n",
      " patients GAVE_CONSENT trial, trial HAS_STOPPING_RULE no stopping rule for futility,\n",
      " patients GAVE_CONSENT trial, trial HAS_ALPHA_LEVEL 0.05,\n",
      " patients GAVE_CONSENT trial, trial HAS_POWER 90%,\n",
      " patients GAVE_CONSENT trial, trial END_DATE April 2017,\n",
      " patients GAVE_CONSENT trial, trial END_DATE June 23, 2015,\n",
      " patients GAVE_CONSENT trial, trial START_DATE March 2013,\n",
      " patients GAVE_CONSENT trial, trial START_DATE September 2, 2008,\n",
      " patients GAVE_CONSENT trial, trial TESTED_IN ketoconazole,\n",
      " patients GAVE_CONSENT trial, trial TESTED_IN lisofylline placebo,\n",
      " patients GAVE_CONSENT trial, trial TESTED_IN ketoconazole placebo,\n",
      " patients GAVE_CONSENT trial, trial TESTED_IN lisofylline,\n",
      " patients GAVE_CONSENT trial, trial HAS_CHARACTERISTIC high adherence to the protocol,\n",
      " patients GAVE_CONSENT trial, trial HAS_CHARACTERISTIC high adherence to the recommended ventilation and fluid strategy,\n",
      " patients GAVE_CONSENT trial, trial HAS_CHARACTERISTIC minimal crossover use of neuromuscular blockade,\n",
      " patients GAVE_CONSENT trial, trial INVOLVES patients with septic shock,\n",
      " patients GAVE_CONSENT trial, trial CONDUCTED_IN United Kingdom,\n",
      " patients GAVE_CONSENT trial, trial CONDUCTED_IN Denmark,\n",
      " patients GAVE_CONSENT trial, trial CONDUCTED_IN Australia,\n",
      " patients GAVE_CONSENT trial, trial CONDUCTED_IN New Zealand,\n",
      " patients GAVE_CONSENT trial, trial CONDUCTED_IN Saudi Arabia,\n",
      " patients GAVE_CONSENT trial, trial ENROLLED_IN 3658 patients,\n",
      " patients GAVE_CONSENT trial, trial ENROLLED_IN 3800 patients,\n",
      " patients GAVE_CONSENT trial, trial ENROLLED_IN 861 patients,\n",
      " patients GAVE_CONSENT trial, trial ENROLLED_IN 1006 patients,\n",
      " patients GAVE_CONSENT trial, trial STOPPED_AT second interim analysis for futility,\n",
      " patients GAVE_CONSENT trial, trial USED two-group parallel design,\n",
      " patients GAVE_CONSENT trial, trial CONDUCTED_BY Acute Respiratory Distress Syndrome Network,\n",
      " patients HAS_DEATH_RATE 29% with response to corticotropin,\n",
      " patients HAS_DEATH_RATE 38% without response to corticotropin,\n",
      " vasopressor or inotropic agents ADMINISTERED_FOR patients,\n",
      " vasopressor or inotropic agents ADMINISTERED_FOR patients, vasopressor or inotropic agents ASSESSED_IN post hoc analyses,\n",
      " patients STATUS_AT day 60,\n",
      " sepsis PRESENCE_OR_ABSENCE_IN patients,\n",
      " sepsis PRESENCE_OR_ABSENCE_IN patients, sepsis ASSOCIATED_WITH dysregulated response of the hypothalamic–pituitary–adrenal axis,\n",
      " patients HAD chronic liver disease,\n",
      " patients HAD chronic liver disease, chronic liver disease DEFINED_BY Child–Pugh class C,\n",
      " human albumin ADMINISTERED_TO patients,\n",
      " human albumin ADMINISTERED_TO patients, human albumin USED_FOR severe sepsis,\n",
      " human albumin ADMINISTERED_TO patients, human albumin PROVIDES intravascular volume,\n",
      " human albumin ADMINISTERED_TO patients, human albumin PROVIDES adequate oncotic pressure,\n",
      " human albumin ADMINISTERED_TO patients, human albumin HAS_CHARACTERISTIC does not provide a survival advantage over crystalloids,\n",
      " human albumin ADMINISTERED_TO patients, human albumin HAS_CHARACTERISTIC safe,\n",
      " patients ENROLLED_WITH_CONDITION qualifying Spo2:Fio2,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS,\n",
      " patients EXCLUDED_REASON bone marrow transplantation or chemotherapy,\n",
      " patients EXCLUDED_REASON improvement in the Pao2:Fio2 before enrollment,\n",
      " patients EXCLUDED_REASON previous receipt of neuromuscular blockade,\n",
      " patients EXCLUDED_IF preexisting conditions with an expected 6-month mortality exceeding 50%,\n",
      " patients EXCLUDED_IF suspected vasculitic pulmonary hemorrhage,\n",
      " patients EXCLUDED_IF at risk for intracranial hypertension,\n",
      " patients EXCLUDED_IF severe chronic respiratory disease,\n",
      " patients EXCLUDED_IF hypoxemia primarily related to left atrial hypertension,\n",
      " patients EXCLUDED_IF expected duration of mechanical ventilation was less than 48 hours,\n",
      " patients EXCLUDED_IF lack of commitment to life support,\n",
      " patients EXCLUDED_IF younger than 16 years of age or older than 85 years of age,\n",
      " patients EXCLUDED_IF neuromuscular disorders that are known to prolong the need for mechanical ventilation,\n",
      " patients UNDERWENT reversal of shock,\n",
      " patients UNDERWENT reversal of shock, reversal of shock HASTENS hydrocortisone,\n",
      " patients UNDERWENT reversal of shock, reversal of shock DOES_NOT_IMPROVE hydrocortisone,\n",
      " patients UNDERWENT bone marrow transplantation,\n",
      " patients UNDERWENT lung transplantation,\n",
      " patients ASSIGNED_TO crystalloid group,\n",
      " patients ASSIGNED_TO crystalloid group, crystalloid group HAS_SHORTER_TIME_TO_SUSPENSION_OF_VASOPRESSORS albumin group,\n",
      " patients ASSIGNED_TO crystalloid group, crystalloid group HAS_LOWER_AVERAGE_CARDIOVASCULAR_SOFA_SUBSCORE albumin group,\n",
      " patients ASSIGNED_TO crystalloid group, crystalloid group HAS_LOWER_HEART_RATE albumin group,\n",
      " patients ASSIGNED_TO crystalloid group, crystalloid group REACHED_TARGET mean arterial pressure,\n",
      " patients ASSIGNED_TO crystalloid group, crystalloid group HAS_OUTCOME_AT_28_DAYS 288 of 900 patients (32.0%),\n",
      " patients ASSIGNED_TO crystalloid group, crystalloid group HAS_LOWER_CUMULATIVE_NET_FLUID_BALANCE_THAN albumin group,\n",
      " patients ASSIGNED_TO crystalloid group, crystalloid group HAS_LOWER_DAILY_NET_FLUID_BALANCE_THAN albumin group,\n",
      " patients ASSIGNED_TO crystalloid group, crystalloid group DATA_AVAILABLE_FOR 893 patients,\n",
      " patients ASSIGNED_TO crystalloid group, crystalloid group EXCLUDED_PATIENTS 1 patient,\n",
      " patients ASSIGNED_TO crystalloid group, crystalloid group HAS_DATA 576 patients,\n",
      " patients ASSIGNED_TO crystalloid group, crystalloid group HAS_LOWER_NET_FLUID_BALANCE albumin group,\n",
      " patients ASSIGNED_TO crystalloid group, crystalloid group HAS_HIGHER_MEAN_ARTERIAL_PRESSURE albumin group,\n",
      " patients ASSIGNED_TO crystalloid group, crystalloid group HAS_DEATH_RATE 43.6% at 90 days,\n",
      " patients ASSIGNED_TO crystalloid group, crystalloid group HAS_DEATH_RATE 32.0% at 28 days,\n",
      " patients ASSIGNED_TO crystalloid group, crystalloid group HAS_OUTCOME new organ failures,\n",
      " patients ASSIGNED_TO crystalloid group, crystalloid group HAS_OUTCOME death at 28 days,\n",
      " patients ASSIGNED_TO crystalloid group, crystalloid group HAS_OUTCOME 43.6% died,\n",
      " patients ASSIGNED_TO crystalloid group, crystalloid group HAS_OUTCOME death at 90 days,\n",
      " patients ASSIGNED_TO crystalloid group, crystalloid group HAS_CHARACTERISTIC lower serum bilirubin concentration,\n",
      " patients ASSIGNED_TO crystalloid group, crystalloid group RECEIVED crystalloid solution alone,\n",
      " patients ASSIGNED_TO albumin group,\n",
      " patients ASSIGNED_TO albumin group, albumin group HAS_SHORTER_TIME_TO_SUSPENSION_OF_VASOPRESSORS crystalloid group,\n",
      " patients ASSIGNED_TO albumin group, albumin group HAS_LOWER_AVERAGE_CARDIOVASCULAR_SOFA_SUBSCORE crystalloid group,\n",
      " patients ASSIGNED_TO albumin group, albumin group HAS_LOWER_HEART_RATE crystalloid group,\n",
      " patients ASSIGNED_TO albumin group, albumin group HAS_OUTCOME_AT_28_DAYS 285 of 895 patients (31.8%),\n",
      " patients ASSIGNED_TO albumin group, albumin group HAS_LOWER_CUMULATIVE_NET_FLUID_BALANCE_THAN crystalloid group,\n",
      " patients ASSIGNED_TO albumin group, albumin group HAS_LOWER_DAILY_NET_FLUID_BALANCE_THAN crystalloid group,\n",
      " patients ASSIGNED_TO albumin group, albumin group DATA_AVAILABLE_FOR 888 patients,\n",
      " patients ASSIGNED_TO albumin group, albumin group EXCLUDED_PATIENTS 2 patients,\n",
      " patients ASSIGNED_TO albumin group, albumin group EXCLUDED_PATIENTS 5 patients,\n",
      " patients ASSIGNED_TO albumin group, albumin group HAS_DATA 582 patients,\n",
      " patients ASSIGNED_TO albumin group, albumin group HAS_LOWER_NET_FLUID_BALANCE crystalloid group,\n",
      " patients ASSIGNED_TO albumin group, albumin group TARGET_SERUM_ALBUMIN 30 g per liter or more,\n",
      " patients ASSIGNED_TO albumin group, albumin group HAS_HIGHER_MEAN_ARTERIAL_PRESSURE crystalloid group,\n",
      " patients ASSIGNED_TO albumin group, albumin group HAS_DEATH_RATE 31.8% at 28 days,\n",
      " patients ASSIGNED_TO albumin group, albumin group HAS_DEATH_RATE 41.1% at 90 days,\n",
      " patients ASSIGNED_TO albumin group, albumin group HAS_OUTCOME new organ failures,\n",
      " patients ASSIGNED_TO albumin group, albumin group HAS_OUTCOME death at 28 days,\n",
      " patients ASSIGNED_TO albumin group, albumin group HAS_OUTCOME 43.6% died,\n",
      " patients ASSIGNED_TO albumin group, albumin group HAS_OUTCOME death at 90 days,\n",
      " patients ASSIGNED_TO albumin group, albumin group HAS_CHARACTERISTIC higher serum bilirubin,\n",
      " patients ASSIGNED_TO albumin group, albumin group HAS_CHARACTERISTIC lower platelet count,\n",
      " patients ASSIGNED_TO albumin group, albumin group RECEIVED 20% albumin and crystalloid solution,\n",
      " patients ASSIGNED_TO study-group assignments,\n",
      " patients ASSIGNED_TO study-group assignments, study-group assignments BLINDED_BY Consolidated Standards for the Reporting of Trials (CONSORT) guidelines,\n",
      " patients HAD_CRITERIA bilateral pulmonary opacities on chest radiography or on computed tomography,\n",
      " patients HAD_CRITERIA Pao2:Fio2 of less than 150 mm Hg with a PEEP of 8 cm or more of water,\n",
      " patients UNDERGOING mechanical ventilation,\n",
      " patients UNDERGOING mechanical ventilation, mechanical ventilation EARLIER_CESSATION hydrocortisone,\n",
      " patients UNDERGOING mechanical ventilation, mechanical ventilation COLLECTED_ON data,\n",
      " patients UNDERGOING mechanical ventilation, mechanical ventilation HAS_SHORTER_TIME_TO_WEANING hydrocortisone-plus-fludrocortisone group,\n",
      " patients UNDERGOING mechanical ventilation, mechanical ventilation ASSIGNED_TO_RECEIVE patients,\n",
      " patients UNDERGOING mechanical ventilation, mechanical ventilation SHORTENED_BY conservative fluid strategy,\n",
      " patients UNDERGOING mechanical ventilation, mechanical ventilation ASSESSED_IN post hoc analyses,\n",
      " patients UNDERGOING mechanical ventilation, mechanical ventilation USED_FOR acute lung injury,\n",
      " patients UNDERGOING mechanical ventilation, mechanical ventilation USED_FOR acute respiratory distress syndrome,\n",
      " patients UNDERGOING mechanical ventilation, mechanical ventilation CONTRIBUTES_TO Multiple system organ failure,\n",
      " patients UNDERGOING mechanical ventilation, mechanical ventilation CAUSES lung injury,\n",
      " patients UNDERGOING mechanical ventilation, mechanical ventilation HAS_TREATMENT acute respiratory distress syndrome,\n",
      " patients UNDERGOING mechanical ventilation, mechanical ventilation USED_IN lower tidal volume,\n",
      " patients UNDERGOING mechanical ventilation, mechanical ventilation PERFORMED_WITH endotracheal tube,\n",
      " patients UNDERGOING mechanical ventilation, mechanical ventilation UNDERGOING Patients with septic shock,\n",
      " patients UNDERGOING mechanical ventilation, mechanical ventilation UNDERGOING patients with septic shock,\n",
      " patients UNDERGOING mechanical ventilation, mechanical ventilation HAS_CHARACTERISTIC lower tidal volume,\n",
      " patients UNDERGOING mechanical ventilation, mechanical ventilation HAS_CHARACTERISTIC lighter sedation targets,\n",
      " patients UNDERGOING mechanical ventilation, mechanical ventilation INVOLVES traditional tidal volumes,\n",
      " patients UNDERGOING mechanical ventilation, mechanical ventilation INVOLVES lower tidal volumes,\n",
      " patients UNDERGOING mechanical ventilation, mechanical ventilation CONDUCTED_IN intensive care unit (ICU),\n",
      " patients UNDERGOING mechanical ventilation, mechanical ventilation AFFECTS survival and outcomes after discharge from the intensive care unit,\n",
      " ASYS trial INCLUDES patients,\n",
      " ASYS trial INCLUDES patients, ASYS trial RECRUITED patients with lung injury,\n",
      " ASYS trial INCLUDES patients, ASYS trial EXCLUDES patients whose Pao2:Fio2 improved to more than 200 mm Hg before randomization,\n",
      " patients MORTALITY_RATE 45%,\n",
      " patients ENROLLED_IN study,\n",
      " patients ENROLLED_IN study, study EXCLUDED 4 participants,\n",
      " patients ENROLLED_IN study, study EXCLUDED 8 participants,\n",
      " patients ENROLLED_IN study, study INCLUDED inclusion and exclusion criteria,\n",
      " patients ENROLLED_IN study, study NOT_DESIGNED_FOR evaluate mortality,\n",
      " patients ENROLLED_IN study, study DESIGNED authors,\n",
      " patients ENROLLED_IN study, study PARTICIPATING_IN intensive care units (ICUs),\n",
      " patients ENROLLED_IN study, study PARTICIPATED_IN study patients and their relatives,\n",
      " patients ENROLLED_IN study, study DETECTED reduction by 10 percentage points,\n",
      " patients ENROLLED_IN study, study HAD_POWER 90 percent,\n",
      " patients ENROLLED_IN study, study HAS_CONDITION early termination if the use of lower tidal volumes was found to be either efficacious or ineffective,\n",
      " patients ENROLLED_IN study, study HAS_BOUNDARY Stopping boundaries (with a two-sided a level of 0.05),\n",
      " patients ENROLLED_IN study, study APPROVED_BY institutional review board,\n",
      " patients ENROLLED_IN study, study APPROVED_BY National Heart, Lung, and Blood Institute,\n",
      " patients ENROLLED_IN study, study WERE_EXCLUDED 1571 Patients,\n",
      " patients ENROLLED_IN study, study WERE_ENROLLED 571 Patients,\n",
      " patients ENROLLED_IN study, study WERE_ELIGIBLE 1149 Patients,\n",
      " patients ENROLLED_IN study, study END_DATE November 2005,\n",
      " patients ENROLLED_IN study, study START_DATE March 2002,\n",
      " patients ENROLLED_IN study, study ENROLLED_IN Patients,\n",
      " patients ENROLLED_IN control group,\n",
      " patients ENROLLED_IN control group, control group HAS_SIMILAR_DURATION ventilation and length of stay in ICU,\n",
      " patients ENROLLED_IN control group, control group HAS_SIMILAR_OUTCOME HFOV group,\n",
      " patients ENROLLED_IN control group, control group HAS_LOWER_INCIDENT barotrauma,\n",
      " patients ENROLLED_IN control group, control group HAS_RATE lower rate of new-onset barotrauma,\n",
      " patients ENROLLED_IN control group, control group HAS_DEATH_RATE 49% (47 of 96 patients) after withdrawal of life support,\n",
      " patients ENROLLED_IN control group, control group HAS_OUTCOME refractory hypoxemia developed in fewer patients,\n",
      " patients ENROLLED_IN control group, control group USED_SEDATION lighter sedation,\n",
      " patients ENROLLED_IN control group, control group HAS_EVENT_COUNT 4 events,\n",
      " patients ENROLLED_IN control group, control group HAS_MORE_EVENTS intervention group,\n",
      " patients ENROLLED_IN control group, control group HAS_PATIENTS 51,\n",
      " patients ENROLLED_IN control group, control group INCLUDED_IN HFOV,\n",
      " patients ENROLLED_IN control group, control group HAS_MORTALITY_RATE 35%,\n",
      " patients ENROLLED_IN control group, control group ASSESSED_AT day 7,\n",
      " patients ENROLLED_IN control group, control group ASSESSED_AT day 28,\n",
      " patients ENROLLED_IN control group, control group RECEIVED_VASOACTIVE_DRUGS 84%,\n",
      " patients ENROLLED_IN control group, control group RECEIVED_NEUROMUSCULAR_BLOCKERS 68%,\n",
      " patients ENROLLED_IN control group, control group DOSE_AMOUNT 141 mg per day,\n",
      " patients ENROLLED_IN control group, control group IN_HOSPITAL_MORTALITY 35%,\n",
      " patients ENROLLED_IN control group, control group RECOMMENDED_USE light sedation,\n",
      " patients ENROLLED_IN control group, control group TARGETS lighter sedation,\n",
      " patients ENROLLED_IN control group, control group RECEIVES usual care without routine neuromuscular blockade,\n",
      " patients ENROLLED_IN control group, control group ASSIGNED_TO hr 506,\n",
      " patients ENROLLED_IN control group, control group ASSIGNED_TO Patients,\n",
      " patients ENROLLED_IN control group, control group HAS_CHARACTERISTIC lighter sedation targets,\n",
      " patients ENROLLED_IN control group, control group MORTALITY_RATE 42.8%,\n",
      " patients ENROLLED_IN control group, control group MEDIAN_DOSE 38 mg,\n",
      " patients ENROLLED_IN control group, control group RECEIVED_TREATMENT neuromuscular blocking agent,\n",
      " patients ENROLLED_IN control group, control group RECEIVED vasoactive drugs,\n",
      " patients ENROLLED_IN control group, control group RECEIVED neuromuscular blockers,\n",
      " patients ENROLLED_IN control group, control group RECEIVED 86 patients,\n",
      " patients ENROLLED_IN control group, control group RECEIVED HFOV for refractory hypoxemia,\n",
      " patients ENROLLED_IN control group, control group RECEIVED usual-care approach without routine neuromuscular blockade and with lighter sedation targets,\n",
      " patients ENROLLED_IN intervention group,\n",
      " patients ENROLLED_IN intervention group, intervention group EXPERIENCED_EFFECT cardiovascular adverse events,\n",
      " patients ENROLLED_IN intervention group, intervention group USED_SEDATION deep sedation,\n",
      " patients ENROLLED_IN intervention group, intervention group HAS_EVENT_COUNT 14 events,\n",
      " patients ENROLLED_IN intervention group, intervention group HAS_MORE_EVENTS control group,\n",
      " patients ENROLLED_IN intervention group, intervention group HAS_PATIENTS 47,\n",
      " patients ENROLLED_IN intervention group, intervention group HAD_LOWER_REQUIREMENT PEEP,\n",
      " patients ENROLLED_IN intervention group, intervention group UNDER_CONDITION deeper sedation,\n",
      " patients ENROLLED_IN intervention group, intervention group ADMINISTERED_TO cisatracurium infusion,\n",
      " patients ENROLLED_IN intervention group, intervention group HAS_MORTALITY_RATE 27%,\n",
      " patients ENROLLED_IN intervention group, intervention group ASSESSED_AT day 7,\n",
      " patients ENROLLED_IN intervention group, intervention group ASSESSED_AT day 28,\n",
      " patients ENROLLED_IN intervention group, intervention group TARGETS deep sedation,\n",
      " patients ENROLLED_IN intervention group, intervention group RECEIVES 48 hours of continuous neuromuscular blockade,\n",
      " patients ENROLLED_IN intervention group, intervention group ASSIGNED_TO Patients,\n",
      " patients ENROLLED_IN intervention group, intervention group PHYSICAL_ACTIVITY less physically active,\n",
      " patients ENROLLED_IN intervention group, intervention group HAD_ADVERSE_EVENTS adverse cardiovascular events,\n",
      " patients ENROLLED_IN intervention group, intervention group MORTALITY_RATE 42.5%,\n",
      " patients ENROLLED_IN intervention group, intervention group MEDIAN_DOSE 1807 mg,\n",
      " patients ENROLLED_IN intervention group, intervention group MEDIAN_DURATION 47.8 hours,\n",
      " patients ENROLLED_IN intervention group, intervention group RECEIVED_TREATMENT continuous infusion of cisatracurium,\n",
      " patients ENROLLED_IN intervention group, intervention group RECEIVED 48-hour continuous infusion of cisatracurium with concomitant deep sedation,\n",
      " patients TREATED_WITH high PEEP strategy,\n",
      " patients TREATED_WITH low tidal volume ventilation,\n",
      " patients TREATED_WITH low tidal volume ventilation, low tidal volume ventilation TREATED_WITH Patients,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients UNDERWENT_BY Mechanical ventilation,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients SCREENED_FOR eligibility criteria,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients MET_CRITERIA_FOR severe sepsis,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients RECEIVED_CARE_FROM clinicians,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients CONDITION septic shock,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients SAFETY_OUTCOME neurologic sequelae,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients SAFETY_OUTCOME gastrointestinal bleeding,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients SAFETY_OUTCOME hyperglycemia,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients SAFETY_OUTCOME superinfection,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients DISCHARGED_BY_DAY day 90,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients DISCHARGED_BY_DAY day 28,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients DISCHARGED_FROM hospital,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients DISCHARGED_FROM ICU,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients OBSERVED_IN severe septic shock,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients HAS_RESPONSE_TO corticotropin,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients HAD_RESPONSE_TO corticotropin,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients USED_BY activated protein C,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients USED_BY antithrombin,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients REMAINS hypotensive after at least 1 hour of resuscitation with fluids and vasopressors,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients RECEIVED_BY Inotropic or vasopressor support,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients RECEIVED_BY renal-replacement therapy,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients MONITORED_FOR cardiovascular, renal, and hepatic failure; coagulation abnormalities; and the need for assisted ventilation,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients HAS_CONDITION septic shock,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients ASSIGNED_TO_RECEIVE mechanical ventilation,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients HAD_CONDITIONS_WITH 6-month mortality rate of more than 50 percent,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients HAD_BURNS_OVER 30 percent of their body-surface area,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients WEIGHED_MORE_THAN 1 kg per centimeter of height,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients GAVE_CONSENT trial,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients HAS_DEATH_RATE 29% with response to corticotropin,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients HAS_DEATH_RATE 38% without response to corticotropin,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients ADMINISTERED_FOR vasopressor or inotropic agents,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients STATUS_AT day 60,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients PRESENCE_OR_ABSENCE_IN sepsis,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients HAD chronic liver disease,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients ADMINISTERED_TO human albumin,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients ENROLLED_WITH_CONDITION qualifying Spo2:Fio2,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients EXCLUDED_REASON bone marrow transplantation or chemotherapy,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients EXCLUDED_REASON improvement in the Pao2:Fio2 before enrollment,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients EXCLUDED_REASON previous receipt of neuromuscular blockade,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients EXCLUDED_IF preexisting conditions with an expected 6-month mortality exceeding 50%,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients EXCLUDED_IF suspected vasculitic pulmonary hemorrhage,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients EXCLUDED_IF at risk for intracranial hypertension,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients EXCLUDED_IF severe chronic respiratory disease,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients EXCLUDED_IF hypoxemia primarily related to left atrial hypertension,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients EXCLUDED_IF expected duration of mechanical ventilation was less than 48 hours,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients EXCLUDED_IF lack of commitment to life support,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients EXCLUDED_IF younger than 16 years of age or older than 85 years of age,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients EXCLUDED_IF neuromuscular disorders that are known to prolong the need for mechanical ventilation,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients UNDERWENT reversal of shock,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients UNDERWENT bone marrow transplantation,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients UNDERWENT lung transplantation,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients ASSIGNED_TO crystalloid group,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients ASSIGNED_TO albumin group,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients ASSIGNED_TO study-group assignments,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients HAD_CRITERIA bilateral pulmonary opacities on chest radiography or on computed tomography,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients HAD_CRITERIA Pao2:Fio2 of less than 150 mm Hg with a PEEP of 8 cm or more of water,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients UNDERGOING mechanical ventilation,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients INCLUDES ASYS trial,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients MORTALITY_RATE 45%,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients ENROLLED_IN study,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients ENROLLED_IN control group,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients ENROLLED_IN intervention group,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients TREATED_WITH high PEEP strategy,\n",
      " patients ENROLLED_WITH_CONDITION moderate-to-severe ARDS, patients TREATED_WITH low tidal volume ventilation,\n",
      " severe sepsis ASSOCIATED_WITH early phase,\n",
      " severe sepsis ASSOCIATED_WITH early phase, severe sepsis HAS_PHYSIOLOGICAL_ADVANTAGE albumin administration,\n",
      " severe sepsis ASSOCIATED_WITH early phase, severe sepsis DIAGNOSED_WITH 1818 patients,\n",
      " severe sepsis ASSOCIATED_WITH early phase, severe sepsis MET_CRITERIA_FOR patient,\n",
      " severe sepsis ASSOCIATED_WITH early phase, severe sepsis MET_CRITERIA_FOR patients,\n",
      " severe sepsis ASSOCIATED_WITH early phase, severe sepsis HAS_ADVANTAGE albumin,\n",
      " severe sepsis ASSOCIATED_WITH early phase, severe sepsis STUDIED_IN tissue factor pathway inhibitor,\n",
      " severe sepsis ASSOCIATED_WITH early phase, severe sepsis USED_FOR human albumin,\n",
      " severe sepsis ASSOCIATED_WITH early phase, severe sepsis FOCUSED_ON Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial,\n",
      " severe sepsis ASSOCIATED_WITH early phase, severe sepsis ASSOCIATED_WITH septic shock,\n",
      " neuromuscular blockade POTENTIATED_BY conditions,\n",
      " neuromuscular blockade POTENTIATED_BY conditions, conditions ANTAGONIZED_BY neuromuscular blockade,\n",
      " neuromuscular blockade ANTAGONIZED_BY conditions,\n",
      " neuromuscular blockade ANTAGONIZED_BY conditions, conditions POTENTIATED_BY neuromuscular blockade,\n",
      " cisatracurium USED_AS neuromuscular blockade,\n",
      " cisatracurium USED_AS neuromuscular blockade, cisatracurium DECREASED incidence of barotrauma,\n",
      " cisatracurium USED_AS neuromuscular blockade, cisatracurium IMPROVED adjusted 90-day survival rate,\n",
      " cisatracurium USED_AS neuromuscular blockade, cisatracurium HAS_BENEFIT improved 90-day survival rate,\n",
      " cisatracurium USED_AS neuromuscular blockade, cisatracurium CAUSED bradycardia,\n",
      " cisatracurium USED_AS neuromuscular blockade, cisatracurium COMPARED_TO placebo,\n",
      " cisatracurium USED_AS neuromuscular blockade, cisatracurium HAS_DIFFERENCE 28-day mortality,\n",
      " cisatracurium USED_AS neuromuscular blockade, cisatracurium HAS_DIFFERENCE ventilator-free days,\n",
      " cisatracurium USED_AS neuromuscular blockade, cisatracurium NOT_ADMINISTERED following 24-hour period,\n",
      " cisatracurium USED_AS neuromuscular blockade, cisatracurium ADMINISTERED_INJECTION 20 mg,\n",
      " cisatracurium USED_AS neuromuscular blockade, cisatracurium EFFECT_ON 90-day mortality,\n",
      " cisatracurium USED_AS neuromuscular blockade, cisatracurium EFFECT_ON end-inspiratory plateau pressure,\n",
      " cisatracurium USED_AS neuromuscular blockade, cisatracurium INCREASED numbers of ventilator-free days,\n",
      " cisatracurium USED_AS neuromuscular blockade, cisatracurium INCREASED days outside the ICU,\n",
      " cisatracurium USED_AS neuromuscular blockade, cisatracurium HAS_EFFECT 31.6% crude 90-day mortality,\n",
      " cisatracurium USED_AS neuromuscular blockade, cisatracurium HAS_EFFECT reduced hazard ratio for death at 90 days,\n",
      " cisatracurium USED_AS neuromuscular blockade, cisatracurium POSSIBLY_RELATED_TO 1 death from complete heart block and refractory shock,\n",
      " cisatracurium USED_AS neuromuscular blockade, cisatracurium WITHDREW_CONSENT 1 patient,\n",
      " cisatracurium USED_AS neuromuscular blockade, cisatracurium DID_NOT_RECEIVE 1,\n",
      " cisatracurium USED_AS neuromuscular blockade, cisatracurium USED_FOR severe ARDS,\n",
      " cisatracurium USED_AS neuromuscular blockade, cisatracurium USED_DOSING_REGIMEN ACURASYS trial,\n",
      " cisatracurium USED_AS neuromuscular blockade, cisatracurium ADMINISTERED_AS rapid, intravenous injection,\n",
      " cisatracurium USED_AS neuromuscular blockade, cisatracurium ADMINISTERED_AS continuous infusion of 37.5 mg per hour for 48 hours,\n",
      " cisatracurium USED_AS neuromuscular blockade, cisatracurium ADMINISTERED_AS intravenous bolus of 15 mg,\n",
      " cisatracurium USED_AS neuromuscular blockade, cisatracurium TARGETS 90-day mortality,\n",
      " cisatracurium USED_AS neuromuscular blockade, cisatracurium ASSIGNED_TO 178 patients,\n",
      " cisatracurium USED_AS neuromuscular blockade, cisatracurium HAS_CHARACTERISTIC same dosing regimen and duration of treatment,\n",
      " cisatracurium USED_AS neuromuscular blockade, cisatracurium MEDIAN_DOSE 38 mg,\n",
      " cisatracurium USED_AS neuromuscular blockade, cisatracurium USED ROSE trial,\n",
      " cisatracurium USED_AS neuromuscular blockade, cisatracurium USED ACURASYS trial,\n",
      " cisatracurium USED_AS neuromuscular blockade, cisatracurium RECEIVED hr 488,\n",
      " cisatracurium USED_AS neuromuscular blockade, cisatracurium AFFECTS 90-day mortality,\n",
      " neuromuscular blockade HAS_CONCERN limited data on the effect of neuromuscular blockade on neuromuscular function and other long-term outcomes,\n",
      " neuromuscular blockade HAS_CONCERN lack of research comparing neuromuscular blockade and deep sedation with current practice,\n",
      " deep sedation REQUIRES neuromuscular blockade,\n",
      " deep sedation REQUIRES neuromuscular blockade, deep sedation USED_SEDATION ACURASYS trial,\n",
      " deep sedation REQUIRES neuromuscular blockade, deep sedation USED_SEDATION intervention group,\n",
      " deep sedation REQUIRES neuromuscular blockade, deep sedation TARGETS intervention group,\n",
      " deep sedation REQUIRES neuromuscular blockade, deep sedation CAN_RESULT_IN negative outcomes,\n",
      " neuromuscular blockade REDUCES accumulation of alveolar fluid,\n",
      " neuromuscular blockade REDUCES work of breathing,\n",
      " neuromuscular blockade REDUCES patient–ventilator dyssynchrony,\n",
      " Increased glucose levels CONTRIBUTED_TO Increased mortality,\n",
      " Increased glucose levels CONTRIBUTED_TO Increased mortality, Increased glucose levels ASSOCIATED_WITH Hydrocortisone group,\n",
      "\n",
      " And Given the following context in the format [(File Name, Text),...] \n",
      "[('ACURASYS.pdf', ' Steroidal  compounds (vecuronium, pancuronium, and ro\\xad cu\\xadronium) may carry the highest risk of myopa- thy,23 although myopathy has also been reported  with benzylisoquinolines, including cisatracuri- um besylate.24,25 Muscle weakness was not in- creased significantly by the use of the neuro- muscular blocking agent in our study. The short  duration of use of the neuromuscular blocking  agent probably explains this result. In conclusion, this multicenter trial provides  evidence that the administration of a neuromuscu- lar blocking agent early in the course of severe  ARDS managed with low-tidal-volume ventilation  may improve outcomes. Future studies are need- ed to replicate and expand these findings before  they can be widely adopted in clinical practice. Supported by the Assistance Publique–Hôpitaux de Marseille  and a grant from the Ministère de')]\n"
     ]
    }
   ],
   "source": [
    "print(\"Context:\", _)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "ename": "NameError",
     "evalue": "name 'context' is not defined",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mNameError\u001b[0m                                 Traceback (most recent call last)",
      "Cell \u001b[0;32mIn[8], line 1\u001b[0m\n\u001b[0;32m----> 1\u001b[0m \u001b[38;5;28mprint\u001b[39m(\u001b[43mcontext\u001b[49m)\n",
      "\u001b[0;31mNameError\u001b[0m: name 'context' is not defined"
     ]
    }
   ],
   "source": [
    "print(context)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "Questions = [\n",
    "    \"Among patients with severe sepsis or septic shock, does administration of albumin 20% solution to maintain serum albumin level ≥3 g/dL (≥30 g/L) reduce all-cause mortality at 28 days when compared to no albumin?\",\n",
    "    \"Among patients with septic shock and relative adrenal insufficiency, do corticosteroids reduce 28-day mortality?\",\n",
    "    \"In adult patients with septic shock, does low-dose hydrocortisone plus fludrocortisone for 7 days affect overall survival at 90 days?\",\n",
    "    \"In patients presenting to an emergency department with severe sepsis or septic shock, does early goal-directed therapy reduce all-cause mortality at 90 days when compared to usual care?\",\n",
    "    \"Among critically ill patients in septic shock, does low-dose hydrocortisone therapy improve survival?\",\n",
    "]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[{'node.id': 'albumin', 'score': 0.9995894432067871}]\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9609296321868896}]\n",
      "[{'node.id': 'shock', 'score': 0.9963037967681885}]\n",
      "[{'node.id': 'The condition', 'score': 0.713494062423706}]\n",
      "[{'node.id': 'seven days', 'score': 0.8874611854553223}]\n",
      "[{'node.id': 'Increased mortality', 'score': 0.9090418815612793}]\n",
      "[{'node.id': 'albumin', 'score': 0.9995894432067871}]\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9609296321868896}]\n",
      "[{'node.id': 'shock', 'score': 0.9963037967681885}]\n",
      "[{'node.id': 'seven days', 'score': 0.8874611854553223}]\n",
      "[{'node.id': 'Corticosteroids', 'score': 0.9996142387390137}]\n",
      "[{'node.id': 'Increased mortality', 'score': 0.9090418815612793}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'Corticosteroids', 'score': 0.9996142387390137}]\n",
      "[{'node.id': 'adrenal insufficiency', 'score': 0.999896764755249}]\n",
      "[{'node.id': 'patients', 'score': 0.8938620090484619}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'Hydrocortisone', 'score': 0.9999010562896729}]\n",
      "[{'node.id': 'Fludrocortisone', 'score': 0.9997668266296387}]\n",
      "[{'node.id': 'seven days', 'score': 0.8874611854553223}]\n",
      "[{'node.id': 'Hydrocortisone', 'score': 0.9999010562896729}]\n",
      "[{'node.id': 'Fludrocortisone', 'score': 0.9997668266296387}]\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9998965263366699}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'emergency department', 'score': 0.9998016357421875}]\n",
      "[{'node.id': 'emergency department', 'score': 0.9998016357421875}]\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9609296321868896}]\n",
      "[{'node.id': 'shock', 'score': 0.9963037967681885}]\n",
      "[{'node.id': 'supportive therapy', 'score': 0.9205706119537354}]\n",
      "[{'node.id': 'Increased mortality', 'score': 0.9090418815612793}]\n",
      "[{'node.id': 'Hydrocortisone', 'score': 0.9999010562896729}]\n",
      "[{'node.id': 'patients', 'score': 0.9984817504882812}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'use of low-dose hydrocortisone', 'score': 0.9833831787109375}]\n",
      "[{'node.id': 'patients', 'score': 0.9984817504882812}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>llama3.1:latest-None</th>\n",
       "      <th>llama3.1:latest-vector</th>\n",
       "      <th>llama3.1:latest-graph</th>\n",
       "      <th>llama3.1:latest-hybrid</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>Question 1</th>\n",
       "      <td>[Based on the context you provided, which is n...</td>\n",
       "      <td>[Based on the provided context, I cannot deter...</td>\n",
       "      <td>[It looks like you've provided a large block o...</td>\n",
       "      <td>[It appears you have a large dataset of statem...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Question 2</th>\n",
       "      <td>[Based on the available evidence, corticostero...</td>\n",
       "      <td>[Based on the provided context, I can identify...</td>\n",
       "      <td>[A very specific and interesting question!\\n\\n...</td>\n",
       "      <td>[It appears that you have provided a list of m...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Question 3</th>\n",
       "      <td>[A great question!\\n\\nBased on the available e...</td>\n",
       "      <td>[Based on the provided context [(File Name, Te...</td>\n",
       "      <td>[It seems like you've provided a large amount ...</td>\n",
       "      <td>[This appears to be a collection of text fragm...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Question 4</th>\n",
       "      <td>[Based on the provided context (which isn't ex...</td>\n",
       "      <td>[Based on the provided context, I can answer y...</td>\n",
       "      <td>[It looks like you've provided a large amount ...</td>\n",
       "      <td>[It appears that you have a large dataset rela...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Question 5</th>\n",
       "      <td>[Based on the provided context, I can provide ...</td>\n",
       "      <td>[Based on the provided context, it appears tha...</td>\n",
       "      <td>[It looks like you've provided a large block o...</td>\n",
       "      <td>[This appears to be a collection of text snipp...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                         llama3.1:latest-None  \\\n",
       "Question 1  [Based on the context you provided, which is n...   \n",
       "Question 2  [Based on the available evidence, corticostero...   \n",
       "Question 3  [A great question!\\n\\nBased on the available e...   \n",
       "Question 4  [Based on the provided context (which isn't ex...   \n",
       "Question 5  [Based on the provided context, I can provide ...   \n",
       "\n",
       "                                       llama3.1:latest-vector  \\\n",
       "Question 1  [Based on the provided context, I cannot deter...   \n",
       "Question 2  [Based on the provided context, I can identify...   \n",
       "Question 3  [Based on the provided context [(File Name, Te...   \n",
       "Question 4  [Based on the provided context, I can answer y...   \n",
       "Question 5  [Based on the provided context, it appears tha...   \n",
       "\n",
       "                                        llama3.1:latest-graph  \\\n",
       "Question 1  [It looks like you've provided a large block o...   \n",
       "Question 2  [A very specific and interesting question!\\n\\n...   \n",
       "Question 3  [It seems like you've provided a large amount ...   \n",
       "Question 4  [It looks like you've provided a large amount ...   \n",
       "Question 5  [It looks like you've provided a large block o...   \n",
       "\n",
       "                                       llama3.1:latest-hybrid  \n",
       "Question 1  [It appears you have a large dataset of statem...  \n",
       "Question 2  [It appears that you have provided a list of m...  \n",
       "Question 3  [This appears to be a collection of text fragm...  \n",
       "Question 4  [It appears that you have a large dataset rela...  \n",
       "Question 5  [This appears to be a collection of text snipp...  "
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "output_df = run_trial(graph, Questions)\n",
    "output_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/var/folders/q4/0d5y6tc142n0r8342v4l5tj40000gn/T/ipykernel_84097/921738572.py:3: FutureWarning: Series.__getitem__ treating keys as positions is deprecated. In a future version, integer keys will always be treated as labels (consistent with DataFrame behavior). To access a value by position, use `ser.iloc[pos]`\n",
      "  output_df[\"llama3.1:latest-hybrid\"][2]\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "['This appears to be a collection of text fragments related to septic shock and the use of hydrocortisone and fludrocortisone as treatments. There are several key points that can be extracted from these texts:\\n\\n1. **Study Context**: The study did not include fludrocortisone, but its results showed a 32% death rate at 28 days in the placebo group.\\n2. **Use of Fludrocortisone**: It is used for septic shock and has been studied in the context of adrenal insufficiency and glucocorticoid therapy.\\n3. **Septic Shock Defined**: Septic shock is defined as the presence of a clinically or microbiologically documented condition associated with cortisol response to corticotrophin, cortisol levels, hydrocortisone, acute respiratory distress syndrome, severe sepsis, and neuromuscular weakness.\\n4. **Treatment for Septic Shock**: Hydrocortisone plus fludrocortisone is used as an adjunctive glucocorticoid therapy for septic shock.\\n5. **Study Results**: The APROCCHSS trial showed a survival benefit with hydrocortisone plus fludrocortisone in adults with septic shock and persistent vasopressor dependency and organ failures.\\n\\nKey terms:\\n\\n- **Fludrocortisone**: Used as a treatment for septic shock, especially in the context of adrenal insufficiency.\\n- **Septic Shock**: A condition defined by various clinical and microbiological criteria associated with cortisol response to corticotrophin, etc.\\n- **Hydrocortisone plus Fludrocortisone**: Used as an adjunctive glucocorticoid therapy for septic shock.\\n- **APROCCHSS trial**: Showed a survival benefit with hydrocortisone plus fludrocortisone in adults with septic shock.\\n\\nThis collection of texts seems to be related to medical research and treatments for septic shock. The primary purpose appears to be an analysis or review of studies and treatments rather than providing a comprehensive overview of the field.']"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# write to csv\n",
    "output_df.to_csv(\"trial1.csv\", index=False)\n",
    "output_df[\"llama3.1:latest-hybrid\"][2]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Trial Setup"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Running trial 0\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9998965263366699}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'albumin', 'score': 0.9995894432067871}]\n",
      "[{'node.id': '20% albumin solution', 'score': 0.8572235107421875}]\n",
      "[{'node.id': '11 patients', 'score': 0.6312956809997559}]\n",
      "[{'node.id': 'G.H.G.', 'score': 0.7848110198974609}]\n",
      "[{'node.id': 'G.H.G.', 'score': 0.7887003421783447}]\n",
      "[{'node.id': 'seven days', 'score': 0.8874611854553223}]\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9998965263366699}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'albumin', 'score': 0.9995894432067871}]\n",
      "[{'node.id': 'The condition', 'score': 0.713494062423706}]\n",
      "[{'node.id': '11 patients', 'score': 0.6312956809997559}]\n",
      "[{'node.id': 'G.H.G.', 'score': 0.7848110198974609}]\n",
      "[{'node.id': 'G.H.G.', 'score': 0.7887003421783447}]\n",
      "[{'node.id': 'seven days', 'score': 0.8874611854553223}]\n",
      "[{'node.id': 'Corticosteroids', 'score': 0.9996142387390137}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'adrenal insufficiency', 'score': 0.999896764755249}]\n",
      "[{'node.id': 'Increased mortality', 'score': 0.9090418815612793}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'Corticosteroids', 'score': 0.9996142387390137}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'Hydrocortisone', 'score': 0.9999010562896729}]\n",
      "[{'node.id': 'Fludrocortisone', 'score': 0.9997668266296387}]\n",
      "[{'node.id': 'adults', 'score': 0.916346549987793}]\n",
      "[{'node.id': 'Hydrocortisone', 'score': 0.9999010562896729}]\n",
      "[{'node.id': 'Fludrocortisone', 'score': 0.9997668266296387}]\n",
      "[{'node.id': 'seven days', 'score': 0.8874611854553223}]\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9998965263366699}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'emergency department', 'score': 0.9998016357421875}]\n",
      "[{'node.id': 'supportive therapy', 'score': 0.9205706119537354}]\n",
      "[{'node.id': 'Increased mortality', 'score': 0.9090418815612793}]\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9998965263366699}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'emergency department', 'score': 0.9998016357421875}]\n",
      "[{'node.id': 'supportive therapy', 'score': 0.9205706119537354}]\n",
      "[{'node.id': 'Increased mortality', 'score': 0.9090418815612793}]\n",
      "[{'node.id': 'Hydrocortisone', 'score': 0.9999010562896729}]\n",
      "[{'node.id': 'patients', 'score': 0.9984817504882812}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'Hydrocortisone', 'score': 0.9999010562896729}]\n",
      "[{'node.id': 'patients', 'score': 0.9984817504882812}]\n",
      "Running trial 1\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9998965263366699}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'albumin', 'score': 0.9995894432067871}]\n",
      "[{'node.id': '20% albumin solution', 'score': 0.8572235107421875}]\n",
      "[{'node.id': '11 patients', 'score': 0.6312956809997559}]\n",
      "[{'node.id': 'G.H.G.', 'score': 0.7848110198974609}]\n",
      "[{'node.id': 'G.H.G.', 'score': 0.7887003421783447}]\n",
      "[{'node.id': 'Increased mortality', 'score': 0.9090418815612793}]\n",
      "[{'node.id': 'seven days', 'score': 0.8874611854553223}]\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9998965263366699}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'albumin', 'score': 0.9995894432067871}]\n",
      "[{'node.id': '20% albumin solution', 'score': 0.8572235107421875}]\n",
      "[{'node.id': '11 patients', 'score': 0.6312956809997559}]\n",
      "[{'node.id': '28 days', 'score': 0.9957969188690186}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'Corticosteroids', 'score': 0.9996142387390137}]\n",
      "[{'node.id': 'adrenal insufficiency', 'score': 0.9505176544189453}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'Corticosteroids', 'score': 0.9996142387390137}]\n",
      "[{'node.id': 'adrenal insufficiency', 'score': 0.999896764755249}]\n",
      "[{'node.id': 'Hydrocortisone', 'score': 0.9999010562896729}]\n",
      "[{'node.id': 'Fludrocortisone', 'score': 0.9997668266296387}]\n",
      "[{'node.id': 'adults', 'score': 0.916346549987793}]\n",
      "[{'node.id': 'Hydrocortisone', 'score': 0.9999010562896729}]\n",
      "[{'node.id': 'Fludrocortisone', 'score': 0.9997668266296387}]\n",
      "[{'node.id': 'seven days', 'score': 0.8874611854553223}]\n",
      "[{'node.id': 'M.P.H.', 'score': 0.6456735134124756}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'emergency department', 'score': 0.9998016357421875}]\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9609296321868896}]\n",
      "[{'node.id': 'shock', 'score': 0.9963037967681885}]\n",
      "[{'node.id': 'supportive therapy', 'score': 0.9205706119537354}]\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9998965263366699}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'emergency department', 'score': 0.9998016357421875}]\n",
      "[{'node.id': 'supportive therapy', 'score': 0.9205706119537354}]\n",
      "[{'node.id': 'Increased mortality', 'score': 0.9090418815612793}]\n",
      "[{'node.id': 'seven days', 'score': 0.8874611854553223}]\n",
      "[{'node.id': 'usual care', 'score': 0.9941277503967285}]\n",
      "[{'node.id': 'Hydrocortisone', 'score': 0.9999010562896729}]\n",
      "[{'node.id': 'patients', 'score': 0.9984817504882812}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'Hydrocortisone', 'score': 0.9999010562896729}]\n",
      "[{'node.id': 'patients', 'score': 0.9984817504882812}]\n",
      "Running trial 2\n",
      "[{'node.id': 'albumin', 'score': 0.9995894432067871}]\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9609296321868896}]\n",
      "[{'node.id': 'shock', 'score': 0.9963037967681885}]\n",
      "[{'node.id': 'The condition', 'score': 0.713494062423706}]\n",
      "[{'node.id': 'serum samples', 'score': 0.8989772796630859}]\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9998965263366699}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': '20% albumin', 'score': 0.9923710823059082}]\n",
      "[{'node.id': 'Medicine', 'score': 0.6795227527618408}]\n",
      "[{'node.id': 'seven days', 'score': 0.8874611854553223}]\n",
      "[{'node.id': 'Increased mortality', 'score': 0.9090418815612793}]\n",
      "[{'node.id': '21', 'score': 0.8776001930236816}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'Corticosteroids', 'score': 0.9996142387390137}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'Corticosteroids', 'score': 0.9996142387390137}]\n",
      "[{'node.id': 'Increased mortality', 'score': 0.9090418815612793}]\n",
      "[{'node.id': 'adults', 'score': 0.916346549987793}]\n",
      "[{'node.id': 'patients', 'score': 0.9984817504882812}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'Hydrocortisone', 'score': 0.9999010562896729}]\n",
      "[{'node.id': 'Fludrocortisone', 'score': 0.9997668266296387}]\n",
      "[{'node.id': 'seven days', 'score': 0.8874611854553223}]\n",
      "[{'node.id': 'Hydrocortisone', 'score': 0.9999010562896729}]\n",
      "[{'node.id': 'Fludrocortisone', 'score': 0.9997668266296387}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'emergency department', 'score': 0.9998016357421875}]\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9998965263366699}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'supportive therapy', 'score': 0.9205706119537354}]\n",
      "[{'node.id': 'Increased mortality', 'score': 0.9090418815612793}]\n",
      "[{'node.id': 'emergency department', 'score': 0.9998016357421875}]\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9609296321868896}]\n",
      "[{'node.id': 'shock', 'score': 0.9963037967681885}]\n",
      "[{'node.id': 'supportive therapy', 'score': 0.9205706119537354}]\n",
      "[{'node.id': 'Hydrocortisone', 'score': 0.9999010562896729}]\n",
      "[{'node.id': 'patients', 'score': 0.9984817504882812}]\n",
      "[{'node.id': 'Hydrocortisone', 'score': 0.9999010562896729}]\n",
      "[{'node.id': 'patients', 'score': 0.9984817504882812}]\n",
      "Running trial 3\n",
      "[{'node.id': 'albumin', 'score': 0.9995894432067871}]\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9609296321868896}]\n",
      "[{'node.id': 'shock', 'score': 0.9963037967681885}]\n",
      "[{'node.id': 'seven days', 'score': 0.8874611854553223}]\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9998965263366699}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': '20% albumin solution', 'score': 0.9958682060241699}]\n",
      "[{'node.id': 'Serum Albumin Levels', 'score': 0.9338665008544922}]\n",
      "[{'node.id': '30 g per liter or more', 'score': 0.7340338230133057}]\n",
      "[{'node.id': '28 days', 'score': 0.9957969188690186}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'adrenal insufficiency', 'score': 0.999896764755249}]\n",
      "[{'node.id': 'Corticosteroids', 'score': 0.9996142387390137}]\n",
      "[{'node.id': 'Corticosteroids', 'score': 0.9996142387390137}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'adrenal insufficiency', 'score': 0.999896764755249}]\n",
      "[{'node.id': 'adults', 'score': 0.916346549987793}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'Hydrocortisone', 'score': 0.9999010562896729}]\n",
      "[{'node.id': 'Fludrocortisone', 'score': 0.9997668266296387}]\n",
      "[{'node.id': 'seven days', 'score': 0.8874611854553223}]\n",
      "[{'node.id': 'patients', 'score': 0.8938620090484619}]\n",
      "[{'node.id': 'Hydrocortisone', 'score': 0.9999010562896729}]\n",
      "[{'node.id': 'Fludrocortisone', 'score': 0.9997668266296387}]\n",
      "[{'node.id': 'seven days', 'score': 0.8874611854553223}]\n",
      "[{'node.id': 'emergency department', 'score': 0.9998016357421875}]\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9609296321868896}]\n",
      "[{'node.id': 'shock', 'score': 0.9963037967681885}]\n",
      "[{'node.id': 'supportive therapy', 'score': 0.9205706119537354}]\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9998965263366699}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'emergency department', 'score': 0.9998016357421875}]\n",
      "[{'node.id': 'supportive therapy', 'score': 0.9205706119537354}]\n",
      "[{'node.id': 'Increased mortality', 'score': 0.9090418815612793}]\n",
      "[{'node.id': 'Hydrocortisone', 'score': 0.9999010562896729}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'Hydrocortisone', 'score': 0.9999010562896729}]\n",
      "[{'node.id': 'patients', 'score': 0.9984817504882812}]\n",
      "Running trial 4\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9998965263366699}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'albumin', 'score': 0.9995894432067871}]\n",
      "[{'node.id': '20% albumin solution', 'score': 0.8572235107421875}]\n",
      "[{'node.id': '11 patients', 'score': 0.6312956809997559}]\n",
      "[{'node.id': '28 days', 'score': 0.9957969188690186}]\n",
      "[{'node.id': 'Increased mortality', 'score': 0.9090418815612793}]\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9998965263366699}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'albumin', 'score': 0.9995894432067871}]\n",
      "[{'node.id': '20% albumin solution', 'score': 0.8572235107421875}]\n",
      "[{'node.id': '11 patients', 'score': 0.6312956809997559}]\n",
      "[{'node.id': 'seven days', 'score': 0.8874611854553223}]\n",
      "[{'node.id': '28 days', 'score': 0.9957969188690186}]\n",
      "[{'node.id': 'Increased mortality', 'score': 0.9090418815612793}]\n",
      "[{'node.id': 'albumin', 'score': 0.9365034103393555}]\n",
      "[{'node.id': 'Corticosteroids', 'score': 0.9996142387390137}]\n",
      "[{'node.id': 'Increased mortality', 'score': 0.9090418815612793}]\n",
      "[{'node.id': 'Corticosteroids', 'score': 0.9996142387390137}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'adrenal insufficiency', 'score': 0.9505176544189453}]\n",
      "[{'node.id': 'Increased mortality', 'score': 0.9090418815612793}]\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "[#DBF0]  _: <CONNECTION> error: Failed to read from defunct connection ResolvedIPv4Address(('34.28.184.63', 7687)) (ResolvedIPv4Address(('34.28.184.63', 7687))): OSError('No data')\n",
      "Unable to retrieve routing information\n",
      "Transaction failed and will be retried in 1.0021246277673463s (Unable to retrieve routing information)\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[{'node.id': 'adults', 'score': 0.916346549987793}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'Hydrocortisone', 'score': 0.9999010562896729}]\n",
      "[{'node.id': 'Fludrocortisone', 'score': 0.9997668266296387}]\n",
      "[{'node.id': 'adults', 'score': 0.916346549987793}]\n",
      "[{'node.id': 'patients', 'score': 0.9984817504882812}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'Hydrocortisone', 'score': 0.9999010562896729}]\n",
      "[{'node.id': 'Fludrocortisone', 'score': 0.9997668266296387}]\n",
      "[{'node.id': 'seven days', 'score': 0.8874611854553223}]\n",
      "[{'node.id': 'emergency department', 'score': 0.9998016357421875}]\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9609296321868896}]\n",
      "[{'node.id': 'shock', 'score': 0.9963037967681885}]\n",
      "[{'node.id': 'supportive therapy', 'score': 0.9205706119537354}]\n",
      "[{'node.id': 'Increased mortality', 'score': 0.9090418815612793}]\n",
      "[{'node.id': 'emergency department', 'score': 0.9998016357421875}]\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9998965263366699}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'supportive therapy', 'score': 0.9205706119537354}]\n",
      "[{'node.id': 'Hydrocortisone', 'score': 0.9999010562896729}]\n",
      "[{'node.id': 'patients', 'score': 0.9984817504882812}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'Hydrocortisone', 'score': 0.9999010562896729}]\n",
      "[{'node.id': 'patients', 'score': 0.9984817504882812}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "Running trial 5\n",
      "[{'node.id': 'albumin', 'score': 0.9995894432067871}]\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9609296321868896}]\n",
      "[{'node.id': 'shock', 'score': 0.9963037967681885}]\n",
      "[{'node.id': 'Medicine', 'score': 0.6795227527618408}]\n",
      "[{'node.id': 'seven days', 'score': 0.8874611854553223}]\n",
      "[{'node.id': 'albumin', 'score': 0.9995894432067871}]\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9609296321868896}]\n",
      "[{'node.id': 'shock', 'score': 0.9963037967681885}]\n",
      "[{'node.id': '11 patients', 'score': 0.6312956809997559}]\n",
      "[{'node.id': 'Corticosteroids', 'score': 0.9996142387390137}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'adrenal insufficiency', 'score': 0.9505176544189453}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'Corticosteroids', 'score': 0.9996142387390137}]\n",
      "[{'node.id': 'Increased mortality', 'score': 0.9090418815612793}]\n",
      "[{'node.id': 'adults', 'score': 0.916346549987793}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'Hydrocortisone', 'score': 0.9999010562896729}]\n",
      "[{'node.id': 'Fludrocortisone', 'score': 0.9997668266296387}]\n",
      "[{'node.id': 'seven days', 'score': 0.8874611854553223}]\n",
      "[{'node.id': 'Hydrocortisone', 'score': 0.9999010562896729}]\n",
      "[{'node.id': 'Fludrocortisone', 'score': 0.9997668266296387}]\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9998965263366699}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'emergency department', 'score': 0.9998016357421875}]\n",
      "[{'node.id': 'supportive therapy', 'score': 0.9205706119537354}]\n",
      "[{'node.id': 'usual care', 'score': 0.9941277503967285}]\n",
      "[{'node.id': 'emergency department', 'score': 0.9998016357421875}]\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9609296321868896}]\n",
      "[{'node.id': 'shock', 'score': 0.9963037967681885}]\n",
      "[{'node.id': 'supportive therapy', 'score': 0.9205706119537354}]\n",
      "[{'node.id': 'Increased mortality', 'score': 0.9090418815612793}]\n",
      "[{'node.id': 'critically ill patients', 'score': 0.9999074935913086}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'Hydrocortisone', 'score': 0.9999010562896729}]\n",
      "[{'node.id': 'supportive therapy', 'score': 0.9205706119537354}]\n",
      "[{'node.id': 'M.P.H.', 'score': 0.6456735134124756}]\n",
      "[{'node.id': 'Hydrocortisone', 'score': 0.9999010562896729}]\n",
      "[{'node.id': 'patients', 'score': 0.9984817504882812}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "Running trial 6\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9998965263366699}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': '20% albumin', 'score': 0.9923710823059082}]\n",
      "[{'node.id': '11 patients', 'score': 0.6312956809997559}]\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9998965263366699}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': '20% albumin', 'score': 0.9923710823059082}]\n",
      "[{'node.id': '11 patients', 'score': 0.6312956809997559}]\n",
      "[{'node.id': 'seven days', 'score': 0.8874611854553223}]\n",
      "[{'node.id': 'Corticosteroids', 'score': 0.9996142387390137}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'Corticosteroids', 'score': 0.9996142387390137}]\n",
      "[{'node.id': 'Increased mortality', 'score': 0.9090418815612793}]\n",
      "[{'node.id': 'patients', 'score': 0.8938620090484619}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'Hydrocortisone', 'score': 0.9999010562896729}]\n",
      "[{'node.id': 'Fludrocortisone', 'score': 0.9997668266296387}]\n",
      "[{'node.id': 'Hydrocortisone', 'score': 0.9999010562896729}]\n",
      "[{'node.id': 'Fludrocortisone', 'score': 0.9997668266296387}]\n",
      "[{'node.id': 'emergency department', 'score': 0.9998016357421875}]\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9609296321868896}]\n",
      "[{'node.id': 'shock', 'score': 0.9963037967681885}]\n",
      "[{'node.id': 'supportive therapy', 'score': 0.9205706119537354}]\n",
      "[{'node.id': 'Increased mortality', 'score': 0.9090418815612793}]\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9998965263366699}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'emergency department', 'score': 0.9998016357421875}]\n",
      "[{'node.id': 'early goal-directed therapy', 'score': 0.9998772144317627}]\n",
      "[{'node.id': 'usual care', 'score': 0.9941277503967285}]\n",
      "[{'node.id': 'Hydrocortisone', 'score': 0.9999010562896729}]\n",
      "[{'node.id': 'patients', 'score': 0.9984817504882812}]\n",
      "[{'node.id': 'Hydrocortisone', 'score': 0.9999010562896729}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "Running trial 7\n",
      "[{'node.id': 'albumin', 'score': 0.9995894432067871}]\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9609296321868896}]\n",
      "[{'node.id': 'shock', 'score': 0.9963037967681885}]\n",
      "[{'node.id': 'The condition', 'score': 0.713494062423706}]\n",
      "[{'node.id': 'seven days', 'score': 0.8874611854553223}]\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9998965263366699}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': '20% albumin solution', 'score': 0.9958682060241699}]\n",
      "[{'node.id': '11 patients', 'score': 0.6312956809997559}]\n",
      "[{'node.id': 'Increased mortality', 'score': 0.9090418815612793}]\n",
      "[{'node.id': 'seven days', 'score': 0.8874611854553223}]\n",
      "[{'node.id': 'G.H.G.', 'score': 0.7848110198974609}]\n",
      "[{'node.id': 'G.H.G.', 'score': 0.7887003421783447}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'Corticosteroids', 'score': 0.9996142387390137}]\n",
      "[{'node.id': 'adrenal insufficiency', 'score': 0.999896764755249}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'Corticosteroids', 'score': 0.9996142387390137}]\n",
      "[{'node.id': 'Increased mortality', 'score': 0.9090418815612793}]\n",
      "[{'node.id': 'patients', 'score': 0.8938620090484619}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'Hydrocortisone', 'score': 0.9999010562896729}]\n",
      "[{'node.id': 'Fludrocortisone', 'score': 0.9997668266296387}]\n",
      "[{'node.id': 'seven days', 'score': 0.8874611854553223}]\n",
      "[{'node.id': 'patients', 'score': 0.8938620090484619}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'Hydrocortisone', 'score': 0.9999010562896729}]\n",
      "[{'node.id': 'Fludrocortisone', 'score': 0.9997668266296387}]\n",
      "[{'node.id': 'seven days', 'score': 0.8874611854553223}]\n",
      "[{'node.id': 'M.P.H.', 'score': 0.6456735134124756}]\n",
      "[{'node.id': 'emergency department', 'score': 0.9998016357421875}]\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9609296321868896}]\n",
      "[{'node.id': 'shock', 'score': 0.9963037967681885}]\n",
      "[{'node.id': 'supportive therapy', 'score': 0.9205706119537354}]\n",
      "[{'node.id': 'seven days', 'score': 0.8874611854553223}]\n",
      "[{'node.id': 'emergency department', 'score': 0.9998016357421875}]\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9609296321868896}]\n",
      "[{'node.id': 'shock', 'score': 0.9963037967681885}]\n",
      "[{'node.id': 'supportive therapy', 'score': 0.9205706119537354}]\n",
      "[{'node.id': 'Increased mortality', 'score': 0.9090418815612793}]\n",
      "[{'node.id': 'seven days', 'score': 0.8874611854553223}]\n",
      "[{'node.id': 'Hydrocortisone', 'score': 0.9999010562896729}]\n",
      "[{'node.id': 'patients', 'score': 0.9984817504882812}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'Hydrocortisone', 'score': 0.9999010562896729}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "Running trial 8\n",
      "[{'node.id': 'albumin', 'score': 0.9995894432067871}]\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9609296321868896}]\n",
      "[{'node.id': 'shock', 'score': 0.9963037967681885}]\n",
      "[{'node.id': 'seven days', 'score': 0.8874611854553223}]\n",
      "[{'node.id': 'albumin', 'score': 0.9995894432067871}]\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9609296321868896}]\n",
      "[{'node.id': 'shock', 'score': 0.9963037967681885}]\n",
      "[{'node.id': 'The condition', 'score': 0.713494062423706}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'Corticosteroids', 'score': 0.9996142387390137}]\n",
      "[{'node.id': 'Increased mortality', 'score': 0.9090418815612793}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'Corticosteroids', 'score': 0.9996142387390137}]\n",
      "[{'node.id': 'Increased mortality', 'score': 0.9090418815612793}]\n",
      "[{'node.id': 'Hydrocortisone', 'score': 0.9999010562896729}]\n",
      "[{'node.id': 'Fludrocortisone', 'score': 0.9997668266296387}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'Hydrocortisone', 'score': 0.9999010562896729}]\n",
      "[{'node.id': 'Fludrocortisone', 'score': 0.9997668266296387}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'emergency department', 'score': 0.9998016357421875}]\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9609296321868896}]\n",
      "[{'node.id': 'shock', 'score': 0.9963037967681885}]\n",
      "[{'node.id': 'supportive therapy', 'score': 0.9205706119537354}]\n",
      "[{'node.id': 'emergency department', 'score': 0.9998016357421875}]\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9998965263366699}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'early goal-directed therapy', 'score': 0.9998772144317627}]\n",
      "[{'node.id': 'usual care', 'score': 0.9941277503967285}]\n",
      "[{'node.id': 'Increased mortality', 'score': 0.9090418815612793}]\n",
      "[{'node.id': 'Hydrocortisone', 'score': 0.9999010562896729}]\n",
      "[{'node.id': 'patients', 'score': 0.9984817504882812}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'Hydrocortisone', 'score': 0.9999010562896729}]\n",
      "[{'node.id': 'patients', 'score': 0.9984817504882812}]\n",
      "Running trial 9\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9998965263366699}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'albumin', 'score': 0.9995894432067871}]\n",
      "[{'node.id': 'The condition', 'score': 0.713494062423706}]\n",
      "[{'node.id': 'Medicine', 'score': 0.6795227527618408}]\n",
      "[{'node.id': 'seven days', 'score': 0.8874611854553223}]\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9998965263366699}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': '20% albumin solution', 'score': 0.9958682060241699}]\n",
      "[{'node.id': '11 patients', 'score': 0.6312956809997559}]\n",
      "[{'node.id': 'Increased mortality', 'score': 0.9090418815612793}]\n",
      "[{'node.id': 'seven days', 'score': 0.8874611854553223}]\n",
      "[{'node.id': 'G.H.G.', 'score': 0.7848110198974609}]\n",
      "[{'node.id': 'G.H.G.', 'score': 0.7887003421783447}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'Corticosteroids', 'score': 0.9996142387390137}]\n",
      "[{'node.id': 'adrenal insufficiency', 'score': 0.999896764755249}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'adrenal insufficiency', 'score': 0.999896764755249}]\n",
      "[{'node.id': 'Corticosteroids', 'score': 0.9996142387390137}]\n",
      "[{'node.id': 'Increased mortality', 'score': 0.9090418815612793}]\n",
      "[{'node.id': 'adults', 'score': 0.916346549987793}]\n",
      "[{'node.id': 'patients', 'score': 0.9984817504882812}]\n",
      "[{'node.id': 'severe sepsis', 'score': 0.8297970294952393}]\n",
      "[{'node.id': 'shock', 'score': 0.9963037967681885}]\n",
      "[{'node.id': 'Hydrocortisone', 'score': 0.9999010562896729}]\n",
      "[{'node.id': 'Fludrocortisone', 'score': 0.9997668266296387}]\n",
      "[{'node.id': 'seven days', 'score': 0.8874611854553223}]\n",
      "[{'node.id': 'Hydrocortisone', 'score': 0.9999010562896729}]\n",
      "[{'node.id': 'Fludrocortisone', 'score': 0.9997668266296387}]\n",
      "[{'node.id': 'emergency department', 'score': 0.9998016357421875}]\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9998965263366699}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'early goal-directed therapy', 'score': 0.9998772144317627}]\n",
      "[{'node.id': 'usual care', 'score': 0.9941277503967285}]\n",
      "[{'node.id': 'severe sepsis', 'score': 0.9998965263366699}]\n",
      "[{'node.id': 'Septic shock', 'score': 0.9999065399169922}]\n",
      "[{'node.id': 'emergency department', 'score': 0.9998016357421875}]\n",
      "[{'node.id': 'Hydrocortisone', 'score': 0.9999010562896729}]\n",
      "[{'node.id': 'patients', 'score': 0.9984817504882812}]\n",
      "[{'node.id': 'Hydrocortisone', 'score': 0.9999010562896729}]\n",
      "[{'node.id': 'patients', 'score': 0.9984817504882812}]\n",
      "[{'node.id': 'shock', 'score': 0.9963037967681885}]\n"
     ]
    }
   ],
   "source": [
    "output_path = \"trial_outputs/\"\n",
    "for i in range(10):\n",
    "    print(f\"Running trial {i}\")\n",
    "    output_df = run_trial(graph, Questions)\n",
    "    output_df.to_csv(output_path + f\"trial{i}.csv\", index=False)\n",
    "    create_md(\n",
    "        output_path + f\"trial{i}.csv\", output_path + f\"trial{i}.md\", questions=Questions\n",
    "    )"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
